Model‐informed drug development (MIDD) has a long and rich history in infectious
diseases. This review describes foundational principles of translational anti‐infective …

In the context of the COVID-19 pandemic, several drugs have been repurposed as potential
candidates for the treatment of COVID-19 infection. While preliminary choices were …

Plitidepsin, a marine-derived cyclic-peptide, inhibits SARS-CoV-2 replication at nanomolar
concentrations by targeting the host protein eukaryotic translation elongation factor 1A …

This study aimed to evaluate the efficacy of favipiravir (FPV) in preventing the development
of severe COVID-19 in patients with mild-to-moderate symptoms. The study evaluated 1037 …

This prospective observational study describes the pharmacokinetic characteristics of
favipiravir in adult patients hospitalized for mild to moderate COVID‐19 with a positive RT …

Aim We hypothesized that viral kinetic modelling could be helpful to prioritize rational drug
combinations for COVID‐19. The aim of this research was to use a viral cell cycle model of …

SARS-CoV-2 is the cause of the COVID-19 pandemic which has claimed more than 6.5
million lives worldwide, devastating the economy and overwhelming healthcare systems …

Background Darunavir is an anti-HIV protease inhibitor repurposed for SARS-CoV-2
treatment. Objective The aim of this study was to assess the population pharmacokinetics of …

Aims Inhaled nebulised unfractionated heparin (UFH) has a strong scientific and biological
rationale that warrants urgent investigation of its therapeutic potential in patients with COVID …

The urgent global public health need presented by severe acute respiratory syndrome‐
coronavirus 2 (SARS‐CoV‐2) has brought scientists from diverse backgrounds together in …